Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 11/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25459137 | 0.91 | ACHE (0.55) | ACHE | |
| SCHEMBL2082535 | 0.72 | L3MBTL1 (0.44) | — | |
| SCHEMBL2084248 | 0.71 | TP53 (0.38) | CHRM2 | |
| SCHEMBL23398172 | 0.71 | CXCR4 (0.42) | CHRM2 | |
| SCHEMBL2665904 | 0.71 | CHRM2 (0.64) | CHRM2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4313288 | 0.71 | ACHE (0.79) | ACHE | |
| SCHEMBL14944806 | 0.70 | CHRM2 (0.56) | CHRM2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14338933 | 0.69 | CHRM2 (0.66) | CHRM2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL24026634 | 0.67 | CHRM2 (0.58) | CHRM2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13985121 | 0.67 | ACHE (0.72) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649235-B2 | Pan-tropic entry inhibitors | EMORY UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210017178-A1 | Pan-Tropic Entry nhibitors | UNIV EMORY (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649235-B2 | Pan-tropic entry inhibitors | CXCR4, CCR5, CXCL12 | CHRM2 3188/4885ACHE 3978/4885HDAC3 819/4885 |
| US-20210017178-A1 | Pan-Tropic Entry nhibitors | CXCR4, CXCL12, CCR5 | CHRM2 3276/4885ACHE 4502/4885HDAC3 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.